0 CHECKOUT

Physician Views: Bayer's M&A Catalyst – is Xofigo a Paradigm Shifter for the Prostate Cancer Market?

  • ID: 2725293
  • December 2013
  • Region: Global
  • FirstWord Publishing
1 of 2

Already positioned as one of the most commercially promising new drug approvals of 2013, Algeta and Bayer's prostate cancer treatment Xofigo is now driving what appears to be the inevitable acquisition of the former by the latter.

Buoyed by a stronger than expected launch in Q3, a number of analysts have speculated that Bayer perceives there to be an increasingly more compelling outlook for Xofigo. One sufficient to drive the diligent German player to move for Algeta, despite the Norwegian company's value already reflecting strong anticipated uptake for the radiopharmaceutical - see In Focus: Bayer's M&A catalyst – the authors speak to Xofigo's lead investigator.

Impressive Q3 sales, and confirmation that Bayer and Algeta are racing towards their target for initialising the specialist treatment centres that are required to prescribe the drug, have helped to diminish fears that Xofigo would face teething troubles due to its status as a radiopharmaceutical.

Longer-term prospects for Xofigo will be shaped by a number of factors, however, not least whether urologists and oncologists prescribe it in combination with other prostate cancer treatments such as READ MORE >

Note: Product cover images may vary from those shown
2 of 2
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Johnson & Johnson Services, Inc.
  • Sanofi S.A.
  • Astellas Pharma, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Astrazeneca PLC
  • Emergent BioSolutions, Inc.